Cancer immunologists and cancer biologists: Why we didn't talk then but need to now

Cancer Research

Volumn 67, Issue 8, 2007, Pages 3500-3504

  Prendergast, George C ^a,b,c   Jaffee, Elizabeth M ^d,e  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; IMATINIB;

CANCER; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER RESEARCH; CELL TRANSFORMATION; CROSS FERTILIZATION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EPIGENETICS; HEREDITY; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ALLERGY AND IMMUNOLOGY; BIOMEDICAL RESEARCH; COMMUNICATION; HUMANS; MOLECULAR BIOLOGY; NEOPLASMS;

EID: 34248545507     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4626     Document Type: Review

References (15)

1. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000;156:361-81.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
3. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-7.
4. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
5. Prendergast GC, editor. Molecular targeted therapeutics: strategies for drug discovery and development. New York: John Wiley & Sons; 2004. p. 351.
6. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74.
7. Muller AJ, Malachowski WP, Prendergast GC. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets 2005;9:831-49.
8. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99:12293-7.
9. Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1 (B7-1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006;119:317-27.
10. Lu LF, Lind EF, Gondek DC, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006;442:997-1002.
11. De Santo C, Serafini P, Marigo I, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A 2005;102:4185-90.
12. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005;5:641-54.
13. + dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 2005;175:5601-5.
14. van der Most RG, Currie A, Robinson BW, Lake RA. Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 2006;66:601-4.
15. Machiels JP, Reilly RT, Emens LA, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001;61:3689-97.